Biodexa wins Health Canada approval to expand Serenta Phase 3 FAP trial into Canada

MIDATECH PHARMA PLC SPON ADS EACH REP 5 ORD

MIDATECH PHARMA PLC SPON ADS EACH REP 5 ORD

BDRX

0.00
  • Biodexa received Health Canada clearance to expand its registrational Phase 3 Serenta trial in familial adenomatous polyposis into Canada.
  • The study targets 168 patients; 73 enrolled so far.
  • Canada is expected to add three to four clinical sites, on top of 29 active recruiting centers in the US and Europe.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodexa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606290830PRIMZONEFULLFEED1001209876) on June 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.